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a  b  s  t  r  a  c  t
Ertapenem  (Invanz®)  is a  newly  developed  carbapenem  -lactam  antimicrobial  agent.  The  drug  usage
in pediatric  age  needs  an  accurate  drug  monitoring  for  effective  patient  management.  The aim  of  this
study  was  to  evaluate  the  use  of  dried  blood  spot  (DBS)  specimens  to measure  ertapenem  concentration
during  treatment.  The  analysis  was  performed  by  UPLC–MS/MS  operating  in multiple  reaction  monitoring
(MRM)  mode.  The  calibration  curve  in  matrix  was  linear  in the  concentration  range of  0.5–100  mg/L with
correlation  coefficient  value  higher  than  0.997.  Performance  parameters  of this  method  like  lower  limit  of
detection  (LLOD,  0.2  mg/L),  lower  limit  of quantification  (LLOQ,  0.5  mg/L),  matrix  effect (20%),  intra-  and
inter-day  imprecision  (CV  within  than  15%)  and  accuracy  (between  94 and  155%)  of  drug  concentrations
have  been  evaluated.  The  drug  stability  at  different  temperatures  was  tested  for  one  month,  to  evaluate
the  risks  of  sample  delivery  at  different  climatic  conditions.
The  reported  method  allows  now  ertapenem  analysis  and  offers  many  advantages  for  patients  including
the  possibility  of  collecting  samples  at  home.
This  new  assay  is  both  precise  and  accurate  and  is  especially  suitable  for  therapeutic  drug  monitoring
and  pharmacokinetic  studies  in neonates  in whom  obtaining  larger  blood  samples  is not  convenient  or
possible.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Ertapenem is a carbapenem antibiotic with a broad spectrum
activity and stability against a wide range of -lactamases. It has
limited activity against Pseudomonas aeruginosa,  enterococci and
methicillin-resistant Staphylococcus aureus and therefore its use
is suggested in moderate-severe community-acquired infections,
rather than in nosocomial infections. Since ertapenem has a good
penetration into intra-abdominal organs and interstitial fluid, it has
been suggested as a therapeutic option in patients with compli-
cated bacterial infections [1].  Recently, internationally guidelines
recommended ertapenem (as other carbapenems) as an alternative
option for the treatment of complicated intra-abdominal infections
(cIAIs) in adults and children aged ≥3 months [2].
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The role of ertapenem in the treatment of complicated bacte-
rial infections in children is, up to now, very limited. Since it has
in vitro activity against the majority of the extended-spectrum beta-
lactamase (ESBL)-producing Escherichia coli and Klebsiella species,
its use in complicated urinary tract infections (cUTIs), other than
in cIAIs, is under investigation [3]. At the present, some infec-
tious disease specialists suggest that ertapenem could be a good
therapeutic option in complicated community-acquired bacterial
infections, reserving the use of antipseudomonal carbapenems
for infections where Pseudomonas aeruginosa is frequently impli-
cated, thus reducing the selective pressure on the selection of
carbapenem-resistant Pseudomonas spp.
Ertapenem has a favorable pharmacokinetic (PK) profile that
allows once-daily (OD) administration in adults after intravenous
and intramuscular administration. Data on PK profile in children
younger than 12 years showed that clearance of ertapenem is about
2-fold higher as compared to adults [4].  Consequently, the recom-
mended intravenous dosage is 1 g OD in patients aged ≥13 years
and 15 mg/kg twice-daily (to a maximum of 1 g/day) in children
aged 3 months to 12 years [4].
0731-7085/$ – see front matter ©  2011 Elsevier B.V. All rights reserved.
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To the best of our knowledge, no pediatric data on ertapenem
PK profile in newborns and children younger than 3 months, nor
PK data after intramuscular administration are available.
Several LC-UV methods have been reported in literature for the
determination of carbapenem antibiotics both in biological sam-
ples such as plasma, serum, urine, bronchial secretions and in tissue
samples. On the other hand, only few LC–MS methods have been
published for the identification and quantization of carbapenem
compounds or their degradation products [5–8]. As is well known,
PK studies are difficult to perform in younger children, since they
require collection of many blood samples in the same day with a
considerable discomfort for the patients. Thus, an attracting and
potential method to easily obtain samples for PK studies in chil-
dren is collection of whole blood samples onto filter paper (dried
blood spot or DBS). DBS specimens are commonly used for neonatal
screening of metabolic diseases, cystic fibrosis and hypothyroidism
in micro-blood samples. Some studies recently evaluated the use
of DBS for therapeutic drug monitoring (TDM) and toxicology in
adults [9,10].  Some studies, also from our group, applied the DBS
technique to evaluate drug concentrations in newborns, infants and
children [11–15].  These reports showed that the accuracy of TDM
studies using DBS is comparable to that of traditional TDM studies
on plasma which require larger blood volumes. The UPLC–MS/MS
method, here described, represents a robust, highly specific
and sensitive approach to quantify ertapenem on dried blood
spots. Sensitivity enhancement, required in quantitative analy-
sis, and also selectivity are obtained acquiring multiple transition
pairs.
2. Materials and methods
2.1. Standards
Ertapenem was provided by Merck Sharp and Dohme (Rome,
Italy). A stock solution of 1 g/L was prepared in water and stored
at −80 ◦C in different aliquots for no longer than six months. Suc-
cessive dilutions were made using HPLC grade water. All chemicals
and solvents were of the highest purity available from commercial
sources and used without any further purification. Analytical grade
methanol, acetonitrile and water were purchased from Panreac
(Barcelona, Spain).
2.2. Sample preparation
Spiking studies were conducted using a pool of human blood
from healthy donors; we evaluated linearity by analyzing forti-
fied 3.2 mm dried blood spots prepared at 0.5, 1.5, 10, 50 and
100 mg/L on filter paper (903®, Whatman GmbH, Dassel Germany).
The amount of blood used to prepare spots was 20 L in order to
produce homogeneous spots [16].
DBS samples were stored at −20 ◦C in a sealed plastic bag
containing desiccant until analysis. One 3.2 mm diameter disk (con-
taining about 3.3–3.4 L of blood) was punched from each DBS
sample and extracted with 200 L of a 30/70 of water/methanol
(v/v) solution. Samples were put in an orbital shaker and kept at
37 ◦C for 25 min. The extracts were transferred into a new 96-well
plate and analyzed immediately.
2.3. Validation procedures
The method was validated in terms of linearity, precision, accu-
racy, extraction recovery, matrix effect and stability. Calibration
curve was prepared by spotting on filter paper spiked human con-
trol blood to obtain concentrations of 0, 0.5, 1.5, 5, 10, 20, 50 and
100 mg/L. Intra-day precision data were evaluated by ten replicate
analysis of five different ertapenem concentrations on the same
day. Inter-day precision data were determined by the analysis of
five different ertapenem concentrations on 10 different days.
To calculate the linear regression, the peak area was  plotted
against the drug concentration in milligrams per liter.
The stability study on DBS samples was  evaluated up to one
month after storage at −20 ◦C, +4 ◦C, room temperature and +37 ◦C.
2.4. Mass spectrometry
The samples and the calibration curve samples were analyzed
on a Agilent (Waldbronn, Germany) 6430 bench-top Triple-Quad
Mass Spectrometer equipped with an Electrospray source (ESI);
the ESI source operated in positive ion mode, using the following
setting: capillary voltage 5000 V, fragmentor voltage 80 V for each
transition, drying gas flow 9 L/min of nitrogen, temperature 325 ◦C,
nebulizer gas 35 psi. The following transitions were monitored in
MRM  mode: m/z 476.2 > 432.2 (quantifier), m/z 476.2 > 390.1 (qual-
ifier) and m/z  476.2 > 233.1 (qualifier). Optimal collision energies
were found at 20, 18, and 18 V, and the resulting cell acceleration
voltage was +7 V for all transitions.
The quantitation experiments were undertaken by using a
Series 1290 Infinity LC System (Agilent Technologies, Waldbronn,
Germany) UHPLC Capillary Pump coupled to an Agilent 6430, both
being fully controlled from the Mass Hunter data system.
The analytical column was an Agilent Zorbax Eclipse Plus C18,
Rapid Resolution 1.8 m,  2.1 mm × 50 mm (Agilent Technologies,
Waldbronn, Germany) operating at 0.4 mL/min flow rate and using
water (A) and acetonitrile (B) both containing 0.1% formic acid as
mobile phase. The column was maintained at 60 ◦C during the run.
The chromatographic separation was obtained using a fast gradi-
ent starting from a 95% of solution A and 5% of solution B. The
95% of organic solvent was  reached in 1 min  and maintained for
15 s; initial conditions were restored in 5 s and the column equi-
librated for 1 min. The total running time was  2.2 min  long and
the ertapenem retention time was fixed to 1.04 min. The eluent
from the column was directed into the Electrospray source with-
out split. Three microliters of the extracted sample were injected
for the UPLC–MS/MS experiments.
System control, data acquisition and interpretation were made
with the Agilent Mass Hunter software (Version B.04.00) soft-
ware including the Qualitative package (for chromatographic and
spectral interpretation) and the Quantitative Software (for quanti-
tative information generation). Calibration curves were set up with
the Mass Hunter Quantitative program using a linear least-square
regression non-weighted.
3. Results and discussion
Dried blood spot sampling is increasingly becoming a good
alternative to traditional plasma samples for biochemical analysis.
The emerging technology offers great opportunities for improved
patient care especially in the pediatric population where is gen-
erally difficult and unethical to obtain sufficient number of blood
samples.
In this work, we  have developed a method for the analysis of
ertapenem concentrations in UPLC–MS/MS performed with only a
few drops of blood and therefore very appealing for its applica-
tion in pharmacokinetic studies involving infants and very young
children. Fig. 1 shows the MS/MS  spectrum obtained by fragment-
ing the precursor ion (476.2 Th) of ertapenem under the above
described conditions. From these experiments, the resulting most
selective ion-pair transition for the quantitative experiment (MRM)
was  476.2 > 432.2 while 476.2 > 390.1 and 476.2 > 233.1 were used
as qualifier transitions.
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Fig. 1. Product ion scan and molecular structure of ertapenem.
Fig. 2. Comparison among the chromatograms from a blank solvent sample spiked with ertapenem (5 mg/L) (C) versus a ertapenem standard solution (5 mg/L) 70/30 of
methanol/water added to an extracted DBS blank sample (B) and an extracted DBS fortified with 5 mg/L of ertapenem (A).
Once the transitions were chosen, sample preparation was opti-
mized adjusting many variables in the extraction process such as
extraction solution composition, volume, time and temperature.
Different extraction solutions were examined and compared
with the objective of choosing the best extraction mixture. The
organic solvents used were methanol or acetonitrile with different
percentages of water (from 50 to 10%). The more efficient extraction
solution, with the highest extraction yield, was found to be 30/70 of
water/methanol (v/v). The volume of extraction solution (200 L)
was chosen in order to combine high extraction capacity with a
minimal sample dilution. A successive extraction using the same
conditions on the exhausted spot produced less than 10% compared
to the first one.We studied the extraction time between 10 and
60 min  but no subsequent increase in the peak area was  reached
after 25 min  (data not shown). Additionally, extraction tempera-
ture was test at 25 ◦C, 37 ◦C and 60 ◦C. The best extraction yield
occurred at 37 ◦C.
Evaluation of drug extraction procedure from DBS, expressed as
the ratio of the areas of the drug fortified DBS extract to that of
blank DBS spiked after extraction was determined to be 15% (Fig. 2,
traces A and B).
Table 1
Intra- and inter-day ertapenem reproducibility on DBS assessed by % CV calculations.
Intraday
Expected concentration
(mg/L)
Mean (n = 10) SD %CV Accuracy %
0.5 0.78 0.04 5.12 155
1.5  1.70 0.12 7.05 113
10  10.47 0.68 6.49 105
50  47.44 2.04 4.30 95
100  102.56 7.53 7.34 103
Interday
Expected concentration
(mg/L)
Mean (n = 10 × 3) SD %CV Accuracy %
0.5 0.53 0.05 9.43 105
1.5  1.49 0.22 14.77 99
10 10.70 1.59 14.86 107
50  46.90 1.60 3.41 94
100 99.44 3.31 3.32 99
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Fig. 3. Stability of ertapenem investigated at 4 different temperatures: −20 ◦C, +4 ◦C, room temperature and +37 ◦C for a month by repeat injection of 3 DBS spiked samples
(5,  20, and 50 mg/L).
Author's personal copy
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The difference between (B) and (A) could be due to a signifi-
cant portion of drug bounded to the blood proteins, as reported
from Musson et al. [17]. This suggested us that the extrac-
tion solution is able to extract the total free ertapenem from
DBS.
We tested also different times to equilibrate the sample after the
ertapenem standard spiking (data not shown) to verify the influ-
ence of time in the protein binding on the free drug portion. The
equilibration time range investigated was from 20 to 120 min  at
room temperature but any changes in the extracted concentration
were observed. Therefore after 20 min  of equilibration, each spiked
blood sample was spotted on filter paper.
Matrix effect is shown by the ratio of extracted DBS sample
spiked post-extraction and spiked solvent sample (Fig. 2, traces B
and C); this value represents a loss of 20% of the analyte signal (ion
suppression) due to alterations in ionization efficiency.
One of the most important features for screening method is
a fast runtime analysis. It allows processing many samples in
a short period of time. Moreover the resolution is another fun-
damental parameter and the column we used was  a 1.8 m
stationary phase column, coupled to a superior specificity of a
triple quadrupole system operating in MS/MS  mode. The injection
volume was maintained low to avoid the system contamination
from the matrix interferences and column over loading. In this
new method the original sample is approximately 60 times diluted
and the sample amount injected is 0.172 L. In these conditions
the sensitivity achieved is enough to afford the analyzed samples,
obtaining robust performances, with the lowest sample prepara-
tion possible. Ertapenem was retained by the column enough to be
separated from the salts, which represents the main ion suppres-
sion source for biological samples analysis. Inter-assay variability
of calibration data obtained over concentrations of 0.5–100 mg/L
was monitored on 4 consecutive weeks. The average slope, inter-
cept, and coefficient of linear regression (r2) were 964, −427 and
0.9987 (SD ± 0.001, range 0.9970–0.9999). A correlation coefficient
>0.9950 is generally considered as the evidence of an acceptable fit
of the data to the regression line.
In order to evaluate punching location impact and the homo-
geneity of drug distribution, experiments on several spots from the
same drop of blood have been performed; no significant differences
were detected. This fact is due to the low spotted volume on paper
(20 L) as elsewhere reported [17].
In order to assess the robustness of the method, five spiked levels
were used (0.5, 1.5, 10, 50 and 100 mg/L) and each was  processed
ten times in one day, resulting in an intra-day repeatability below
7% for all values (Table 1). The inter-day repeatability obtained in
four separate assays for four weeks was better than 15% (Table 1).
The limit of detection (LOD) and lower limit of quantification (LLOQ)
of this method were determined from the coefficient of variation
of a known concentration of reference standards. The LOD for this
assay, calculated from 5 times the noise level of the response, in
DBS was 0.2 mg/L. The LLOQ for this assay calculated from 15 times
the noise level of the response, is 0.5 mg/L.
We investigated the effect of storage time and storage tempera-
ture at four different concentration levels (0.5, 5, 20 and 50 mg/L) on
spiked DBS samples. Ertapenem seems to be not stable under the
tested temperatures (+4 ◦C, room temperature and +37 ◦C), with
the exception of −20 ◦C (Fig. 3). In literature data related to the
ertapenem stability reported a rapid degradation in solution and for
long-term storage freeze at −20 ◦C is required [7,16].  Data related
to the LLOQ (0.5 mg/L) stability are not shown in Fig. 3, because
of the drug concentration after 24 h decreased under the limit
of quantification. Usually the DBS sampling procedure helps the
molecule stabilization, allowing collection, shipping and delivery at
room temperature [16,18]. In this case the DBS sampling advantage
remains, but the shipment must be performed at −20 ◦C.
Fig. 4. Relationship between ertapenem levels in plasma and corresponding dried
blood spots. Values represent the mean of duplicate experiments.
To verify the correlation between data obtained on dried blood
spot and plasma, since no patients receiving ertapenem were
available, three different blood samples at distinct hematocrit lev-
els (low, medium and high) from healthy donors were selected.
For each blood sample three aliquots were prepared and spiked
at 5, 10 and 20 mg/L of ertapenem. Samples were equilibrated for
20 min, then 20 L of blood were spotted on paper and the remain-
ing blood was  centrifuged to obtain plasma. The DBS samples were
extracted as reported in Section 2; 200 L of extraction mixture
were added to 2 L of plasma, vortexed and centrifuged to pre-
cipitate proteins. Three microliters of supernatant were injected.
A good correlation (R2 = 0.9850) between ertapenem plasma and
ertapenem levels measured in the corresponding DBS after real
haematocrit correction was observed (Fig. 4). This confirms the
validity of DBS analysis as an alternative to plasma drug.
The method will be helpful in processing large number of sam-
ples for patient’s treatment monitoring at follow-up. Use of DBS  for
sampling requires little volume of blood spotted and dried on card,
with great advantages over conventional plasma sampling being
less invasive, particularly in pediatric population.
4. Conclusions
The use of DBS offers an easy way of collecting, storing, and
shipping samples and is a non-invasive method because blood can
be obtained from finger pricks sampling.
In order to keep stability for long term storage, ertapenem
should be stored at low temperature (−20 ◦C).
A good correlation between drug levels measured in plasma and
in the corresponding DBS after correction for real hematocrit was
observed.
In this work, we  developed a method for the “on DBS assay”
of ertapenem by using UPLC–MS/MS. It could be considered very
appealing for its application for TDM or in pharmacokinetic studies
involving infants and very young children.
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